#### IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS **MARSHALL DIVISION**

ALLERGAN, INC.,

Plaintiff,

v.

Civil Action No. 2:15-cv-1455 WCB LEAD

JURY TRIAL DEMANDED

TEVA PHARMACEUTICALS USA, INC., et al.,

Defendants.

## **RESPONSE TO DOCKET NO. 377**

The Court's July 25 Order (Dkt. 377) directed the parties to identify "individual patent claim(s)—of the unselected 144 claims—that they believe present unique limitations as to infringement and invalidity." (Dkt. 377 at 2.) With the Court's additional guidance from that Order, Allergan now appreciates that the Court understood Allergan to have chosen "representative" claims in the claim narrowing process. With that additional guidance, Allergan's position is that the thirteen selected claims<sup>1</sup> should be ordered to be representative of the four asserted patents from which the claims originate, the '111 patent, the '048 patent, the '930 patent, and the '191 patent. Thus, resolution of infringement and validity issues on these thirteen claims should resolve those issues as to all claims from the four asserted patents, and there would be no additional issues of infringement and validity to be tried.<sup>2</sup>

Allergan narrowed its case to thirteen claims in response to the Court's urging and Defendants' motion to limit the number of asserted claims. (D.I. 238; Claim Construction Hr'g Tr. (Aug. 26, 2016) at 118:3-120:10.) In doing so, Allergan emphasized the due process concerns associated with forced claim reduction, particularly given the unique posture of Hatch-Waxman cases. (*See* D.I. 246 at 5, 6.) Allegan noted that each patent claim is a separate and independent property right, *Honeywell Int'l Inc. v. Hamilton Sundstrand Corp.*, 370 F.3d 1131, 1148 (Fed. Cir. 2004), and, as the Supreme Court has repeatedly held, a patent claim cannot be taken from a patentee without due process, *Florida Prepaid Postsecondary Educ. Expense Bd. v. Coll. Sav. Bank*, 527 U.S. 627, 642 (1999). (*Id.* at 5.) Based on these principles, Allergan stated

<sup>&</sup>lt;sup>1</sup> The thirteen asserted claims are as follows: claims 26 and 27 of U.S. Patent No. 8,629,111; claims 1, 11, 13, 14, and 23 of U.S. Patent No. 8,648,048; claim 35 of U.S. Patent No. 8,685,930; and claims 13, 16, 22, 26, and 27 of U.S. Patent No. 9,248,191.

<sup>&</sup>lt;sup>2</sup> If the Court orders the claims to be representative, Allergan is prepared to grant Defendants a covenant not to sue on the two unasserted patents—the '162 patent and the '556 patent—with respect to the ANDAs at issue in this case.

that, although the Court can order a patentee to reduce the number of claims for efficiency purposes, "the patentee must be permitted to bring another suit on the unasserted claims." (*Id.* at 5; *see also* Dkt. 261 at 4 ("If Allergan loses on a reduced set of claims in a first trial, a generic company may be able to launch its product before Allergan can file a second suit on its unselected claims.").) In their reply, Defendants *agreed* with Allergan's understanding:

Allergan cites *Alexsam*, where the Court found that when a plaintiff voluntarily withdrew certain claims, which were not presented to the jury at trial, the defendant was not entitled to judgment as a matter of law on those claims. *Alexsam, Inc. v. The Gap, Inc.*, No. 2:13-cv-0004, Dkt. No. 276, slip op, at \*2 (E.D. Tex. May 12, 2014). This is as unsurprising as it is irrelevant to the current motion. *Ordering Allergan to reduce its asserted claims to a reasonable amount has no effect on its unasserted claims.* 

(Dkt. 253 at 3 (emphasis added).)

While briefing on this issue was ongoing, the Court held a telephonic hearing on January 11, 2017 to address other pending motions. During the hearing, the Court again urged Allergan to promptly reduce the number of asserted claims.<sup>3</sup> In response, Allergan proposed a staged reduction in claims, whereby it would reduce the number of asserted claims to no more than 25 claims within one week after Defendants served their final contentions, and then to no more than 15 claims within two weeks of the close of expert discovery. (Dkt. 261 at 3-4.) Allergan reiterated its due process concerns and again emphasized that, although the value of its unselected claims would be eroded by a generic launch, it still retained the ability to assert the unselected claims against Defendants in a second action. (Dkt. 261 at 4.)

The Court ultimately denied Defendants' motion and adopted the proposed staged reduction. (See Dkt. 265.) Allergan reduced its asserted claims accordingly. This issue is back

 $<sup>^3</sup>$  Due to a technical malfunction, a transcript of the telephonic hearing is not available. (*See* Minute Entry from 1/1/17 Motion Hearing.)

#### Case 2:15-cv-01455-WCB Document 385 Filed 07/28/17 Page 4 of 6 PageID #: 16529

before the Court, however, because Defendants apparently now demand resolution with respect to all unselected claims. Defendants' new position is in direct contravention to what they represented to Allergan and the Court—namely, that the reduction of asserted claims would have "no effect on [Allergan's] unasserted claims." (Dkt. 253 at 3.)

Nonetheless, Allergan understands the Court's view on the representative nature of the claims selected. Allergan thus agrees that the thirteen claims should be ordered to be "representative" of the four asserted patents from which the claims originate—meaning that the resolution of questions of infringement and invalidity with respect to the thirteen claims will extend to all unselected claims from the four asserted patents. The Federal Circuit has previously affirmed such a procedure—where the district court extended its finding that representative claims were valid and infringed to all unselected claims—stating that the district court's decision was "clearly and unequivocally devoid of error." *Panduit Corp. v. Dennison Mfg. Co., Inc.*, 836 F.2d 1329, 1331 (Fed. Cir. 1987). If the claims are ordered to be representative, then, consistent with the Court's request in Docket No. 377, there are no additional issues of infringement and validity to be tried.

Dated: July 28, 2017

DOCKF

Respectfully submitted,

FISH & RICHARDSON P.C.

By: <u>/s/ Joseph A. Herriges</u> Jonathan E. Singer (CA Bar No. 187908, MN Bar No. 283459) LEAD ATTORNEY singer@fr.com Juanita R. Brooks (CA Bar No. 75934) brooks@fr.com 12390 El Camino Real San Diego, CA 92130 Telephone: 858-678-5070 Facsimile: 858-678-5099 Michael J. Kane (MN Bar No. 0247625) kane@fr.com Deanna J. Reichel (MN Bar No. 0326513) reichel@fr.com Joseph A. Herriges (MN Bar No. 390350) herriges@fr.com 60 South Sixth Street, #3200 Minneapolis, MN 55402 Telephone: (612) 335-5070 Facsimile: (612) 288-9696

Douglas E. McCann (DE Bar No. 3852) dmccann@fr.com Susan Morrison (DE Bar No. 4690) morrison@fr.com Robert M. Oakes (DE Bar No. 5217) oakes@fr.com 222 Delaware Avenue, 17th Floor Wilmington, DE 19801 Telephone: (302) 652-5070 Facsimile: (302) 652-0607

J. Wesley Samples (OR Bar No. 121784) samples@fr.com 901 15th Street, N.W., 7th Floor Washington, D.C. 20005 Telephone: (202) 783-5070 Facsimile: (202) 783-2331

T. John Ward, Jr. State Bar No. 00794818 E-mail: jw@wsfirm.com Wesley Hill State Bar No. 24032294 E-mail: wh@wsfirm.com Claire Abernathy Henry State Bar No. 24053063 E-mail: claire@wsfirm.com Andrea L. Fair State Bar No. 24078488 E-mail: andrea@wsfirm.com WARD, SMITH & HILL, PLLC 1507 Bill Owens Parkway Longview, Texas 75604 Telephone: (903) 757-6400 Facsimile: (903) 757-2323

COUNSEL FOR PLAINTIFF ALLERGAN, INC.

# DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

# API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.